Business
DXS INTERNATIONAL PLC (AQSE: DXSP): Trading ...
DXS International plc expects its financial year to 30 April 2026 to show group turnover of approximately £3.4 million, marginally lower than the previous year primarily due to reduced R&D tax credit income, but anticipates a small profit, a significant improvement from the prior year's £90,000 loss, reflecting operational discipline and cost control. The company's balance sheet has strengthened through debt-to-equity conversions, and its new NexGen referral solution is showing positive results with ten pilot deployments active and a 94% form completion rate, leading to early user adoption. Despite short-term delays in NHS decision-making due to restructuring, DXS sees long-term opportunities as Integrated Care Boards consolidate, and existing agreements have been extended to September 2027, with the company remaining positive about future growth prospects. Disclaimer*
About this update from Dxs International Plc
DXS INTERNATIONAL PLC (AQSE: DXSP): Trading Update The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon publication of this announcement, this inside information is now considered to be in the public domain. 2 July 2026 DXS INTERNATIONAL PLC (AQSE: DXSP) Trading Update DXS International plc ("the Company" or " AQSE: DXSP" ), the UK healthcare technology provider, today provides a trading update for the financial year to 30 April 2026, ahead of the publication of its audited results for the year ended 30 April 2026. The Company expects to announce its full-year results on or before 18th September 2026. For the year under review, Group turnover is expected to be marginally lower than the previous financial year, with annual revenues of approximately £3.4 million. The reduction primarily reflects lower R&D tax credit income recognised in the period. Despite this modest reduction in revenue, the Board is pleased to report that the Company expects to deliver a small profit for the year, representing a meaningful improvement from the prior year's loss of approximately £90,000. This reflects continued operational discipline and management focus on efficiency and cost control. The Group's balance sheet position has also strengthened during the year under review. The Board would like to recognise and thank both management and shareholders for their support and commitment through debt-to-equity of accrual and loan conversions completed at prices significantly above prevailing market levels. These transactions demonstrate a strong belief in the long-term potential of the business and confidence in the Company's strategy and prospects. Operationally, the Company has made encouraging progress with its newly developed NexGen referral solution, which has been undergoing customer trials with highly positive outcomes. Importantly as at 30 June 2026, ten pilot deployments are active, with more than 100 referral forms configured and a form completion rate of 94%. Although the pilots were established as test deployments only, participating practices have already begun using the system for live referrals...
View stock analysis, news, and events for Dxs International Plc